Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of “Moderate Buy” by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $19.2857.

CADL has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. Bank of America lifted their target price on Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Thursday, August 13th.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider owned 77,362 shares in the company, valued at $778,261.72. The trade was a 23.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 37,447 shares of company stock valued at $390,017 over the last 90 days. 14.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Candel Therapeutics in the 2nd quarter worth about $51,181,000. Vanguard Group Inc. grew its position in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock worth $10,236,000 after purchasing an additional 219,563 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Candel Therapeutics by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock worth $5,524,000 after purchasing an additional 49,315 shares during the period. Halter Ferguson Financial Inc. raised its position in shares of Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after buying an additional 155,996 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Candel Therapeutics by 15.0% in the fourth quarter. State Street Corp now owns 792,218 shares of the company’s stock valued at $4,476,000 after buying an additional 103,452 shares during the period. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Stock Performance

Shares of CADL stock opened at $12.60 on Wednesday. The stock has a market cap of $964.15 million, a PE ratio of -8.94 and a beta of -0.48. The stock has a 50-day moving average of $11.07 and a 200-day moving average of $8.27. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. Candel Therapeutics has a one year low of $4.35 and a one year high of $14.00.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28). As a group, sell-side analysts expect that Candel Therapeutics will post -1.29 earnings per share for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.